Related Experiment Video
Updated: Nov 27, 2025
07:50
A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
Published on: January 29, 2017
9.9K
Recalcitrant Hailey-Hailey Disease Successfully Treated with Low-dose Naltrexone
McBride Michael1,2,3, Witkoff Benjamin M1,2,3, Trotter Shannon C1,2,3
1Dr. McBride is a dermatology resident with HonorHealth/Affiliated Dermatology in Phoenix, Arizona.
The Journal of Clinical and Aesthetic Dermatology
|December 7, 2020
Summary
Low-dose naltrexone (LDN) shows promise for treating Hailey-Hailey disease (HHD), a rare blistering disorder. This study highlights LDN
Area of Science:
- Dermatology
- Genetics
- Pharmacology
Background:
- Hailey-Hailey disease (HHD), or benign familial chronic pemphigus, is a rare, inherited blistering disorder.
- HHD is characterized by recurrent, erosive vesicles and plaques, often resistant to conventional treatments.
Observation:
- A 50-year-old female patient with a 20-year history of biopsy-proven HHD presented with painful, pruritic lesions.
- The patient had previously shown resistance to multiple treatment modalities.
Findings:
- Treatment with low-dose naltrexone (LDN) resulted in significant clinical improvement of HHD lesions within 26 days.
- LDN demonstrated rapid efficacy in managing recalcitrant cutaneous manifestations of HHD.
Implications:
- Low-dose naltrexone (LDN) represents a potential novel therapeutic option for patients with resistant Hailey-Hailey disease.
- Dermatologists should consider LDN as a viable treatment for recalcitrant HHD cases.
- Further research into LDN for HHD management is warranted.
Related Concept Videos
01:27Phase I Reactions: Reductive Reactions
406
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
406
01:10Retrovirus Life Cycles
48.5K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.5K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
452
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
452
01:26Nephrotic Syndrome II : Assessment and Medical Management
87
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
87
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
300
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
300
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
334
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
334